Necroptotic cell binding of β
Animals
Antigen Presentation
/ immunology
Antigen-Presenting Cells
/ metabolism
Apoptosis
Autoantibodies
/ immunology
Autoantigens
/ immunology
Cell Line
Cytokines
/ metabolism
Dendritic Cells
/ metabolism
Histocompatibility Antigens Class II
/ metabolism
Inflammation Mediators
/ metabolism
Lipopolysaccharides
/ pharmacology
Lupus Erythematosus, Systemic
/ immunology
Mice, Inbred C57BL
Necroptosis
/ immunology
Protein Binding
Protein Kinases
/ metabolism
Receptor-Interacting Protein Serine-Threonine Kinases
/ metabolism
beta 2-Glycoprotein I
/ metabolism
autoantibodies
autoantigens
necroptosis
systemic lupus erythematosus
β2-glycoprotein I
Journal
Immunology and cell biology
ISSN: 1440-1711
Titre abrégé: Immunol Cell Biol
Pays: United States
ID NLM: 8706300
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
07
11
2018
revised:
07
06
2019
accepted:
08
06
2019
pubmed:
13
6
2019
medline:
18
4
2020
entrez:
13
6
2019
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is characterized by the development of autoantibodies against diverse self-antigens with damage to multiple organs. Immunization with the SLE autoantigen β
Substances chimiques
Autoantibodies
0
Autoantigens
0
Cytokines
0
Histocompatibility Antigens Class II
0
Inflammation Mediators
0
Lipopolysaccharides
0
beta 2-Glycoprotein I
0
MLKL protein, mouse
EC 2.7.-
Protein Kinases
EC 2.7.-
Receptor-Interacting Protein Serine-Threonine Kinases
EC 2.7.11.1
Ripk3 protein, mouse
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
799-814Subventions
Organisme : Canadian Institutes of Health Research (CIHR)
ID : MOP-67101
Pays : International
Organisme : Canadian Institutes of Health Research (CIHR)
ID : MOP-97916
Pays : International
Organisme : Canadian Institutes of Health Research (CIHR)
ID : PJT-159652
Pays : International
Informations de copyright
© 2019 Australian and New Zealand Society for Immunology Inc.
Références
Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-1330.
Levine JS, Subang R, Nasr SH, et al. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol 2006; 177: 6504-6516.
Jung JY, Suh CH. Incomplete clearance of apoptotic cells in systemic lupus erythematosus: pathogenic role and potential biomarker. Int J Rheum Dis 2015; 18: 294-303.
Podolska MJ, Biermann MH, Maueroder C, Hahn J, Herrmann M. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res 2015; 8: 161-171.
Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol 2011; 187: 2405-2417.
Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196: 1091-1097.
Su RJ, Epp A, Latchman Y, Bolgiano D, Pipe SW, Josephson NC. Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts. Mol Ther 2010; 18: 214-222.
Galluzzi L, Bravo-San Pedro JM, Vitale I, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015; 22: 58-73.
Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-120.
Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370: 455-465.
Newton K, Manning G. Necroptosis and Inflammation. Annu Rev Biochem 2016; 85: 743-763.
Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311-320.
Vanden Berghe T, Grootjans S, Goossens V, et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods 2013; 61: 117-129.
Gong YN, Guy C, Olauson H, et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell 2017; 169: 286-300. e216.
Gunther C, Martini E, Wittkopf N, et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 335-339.
Ofengeim D, Ito Y, Najafov A, et al. Activation of necroptosis in multiple sclerosis. Cell Rep 2015; 10: 1836-1849.
Pierdomenico M, Negroni A, Stronati L, et al. Necroptosis is active in children with inflammatory bowel disease and contributes to heighten intestinal inflammation. Am J Gastroenterol 2014; 109: 279-287.
Aaes TL, Kaczmarek A, Delvaeye T, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 2016; 15: 274-287.
Collins CC, Bashant K, Erikson C, et al. Necroptosis of dendritic cells promotes activation of γδ T cells. J Innate Immun 2016; 8: 479-492.
Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8+ T cells. Science 2015; 350: 328-334.
Takahashi N, Duprez L, Grootjans S, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
Fan H, Liu F, Dong G, et al. Activation-induced necroptosis contributes to B-cell lymphopenia in active systemic lupus erythematosus. Cell Death Dis 2014; 5: e1416.
Fenton K. The effect of cell death in the initiation of lupus nephritis. Clin Exp Immunol 2015; 179: 11-16.
Price BE, Rauch J, Shia MA, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner. J Immunol 1996; 157: 2201-2208.
Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
Salem D, Subang R, Okazaki Y, et al. β2-Glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantibodies. J Biol Chem 2015; 290: 5543-5555.
Laplante P, Fuentes R, Salem D, et al. Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4. Lupus 2016; 25: 162-176.
Balasubramanian K, Schroit AJ. Characterization of phosphatidylserine-dependent β2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem 1998; 273: 29272-29277.
Cocca BA, Seal SN, D'Agnillo P, et al. Structural basis for autoantibody recognition of phosphatidylserine-β2 glycoprotein I and apoptotic cells. Proc Natl Acad Sci USA 2001; 98: 13826-13831.
Pittoni V, Ravirajan CT, Donohoe S, MacHin SJ, Lydyard PM, Isenberg DA. Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and β2-glycoprotein I (β2-GPI) on apoptotic cells. Clin Exp Immunol 2000; 119: 533-543.
Levine JS, Subang R, Koh JS, Rauch J. Induction of anti-phospholipid autoantibodies by β2-glycoprotein I bound to apoptotic thymocytes. J Autoimmun 1998; 11: 413-424.
de Groot PG, de Laat B. Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Best Pract Res Clin Rheumatol 2017; 31: 334-341.
Salem D, Subang R, Kuwana M, Levine JS, Rauch J. T cells from induced and spontaneous models of SLE recognize a common T cell epitope in β2-glycoprotein I. Cell Mol Immunol 2018 [Epub ahead of print]. https://doi.org/10.1038/s41423-018-0013-3
Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol 2017; 18: 127-136.
Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol 2004; 24: 1464-1469.
Cocca BA, Cline AM, Radic MZ. Blebs and apoptotic bodies are B cell autoantigens. J Immunol 2002; 169: 159-166.
Orozco S, Oberst A. RIPK3 in cell death and inflammation: the good, the bad, and the ugly. Immunol Rev 2017; 277: 102-112.
Newton K, Dugger DL, Maltzman A, et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ 2016; 23: 1565-1576.
Negroni A, Colantoni E, Pierdomenico M, et al. RIP3 AND pMLKL promote necroptosis-induced inflammation and alter membrane permeability in intestinal epithelial cells. Dig Liver Dis 2017; 49: 1201-1210.
Honarpisheh M, Desai J, Marschner JA, et al. Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis. Biosci Rep 2016; 36: e00425.
Corradetti C, Jog NR, Gallucci S, Madaio M, Balachandran S, Caricchio R. Immune-mediated nephropathy and systemic autoimmunity in mice does not require receptor interacting protein kinase 3 (RIPK3). PLoS ONE 2016; 11: e0163611.
Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 2018; 25: 486-541.
Zhang J, Qin D, Yang YJ, et al. MLKL deficiency inhibits DSS-induced colitis independent of intestinal microbiota. Mol Immunol 2019; 107: 132-141.
Moriwaki K, Balaji S, McQuade T, Malhotra N, Kang J, Chan FK. The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair. Immunity 2014; 41: 567-578.
Downey J, Pernet E, Coulombe F, et al. RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection. PLoS Pathog 2017; 13: e1006326.
Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol 2014; 192: 5459-5468.
Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol 2018; 14: 214-228.
Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-181.
Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207-210.
Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
Wu J, Huang Z, Ren J, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res 2013; 23: 994-1006.
Stockinger B, Zal T, Zal A, Gray D. B cells solicit their own help from T cells. J Exp Med 1996; 183: 891-899.